Rodman & Renshaw Initiates Coverage of Enzo Biochem (ENZ) with a Market Outperform
More News related to ENZ
- Enzo Biochem, Inc. Announces Departure of Its Secretary and Treasurer
- Enzo Biochem's Clinical Lab Enters Exclusive Agreement with GeneNews to Market Blood Test for Colorectal Cancer
- GeneNews partners with Enzo Clinical Labs to market ColonSentry(TM) in the U.S.
- Enzo Biochem Executive to Discuss Oral Immune Regulation Platform at Windhover TA Partnerships 2009 Conference
- Enzo Biochem to Present at Lazard Capital Markets 6th Annual Healthcare Conference
More News related to New Coverage
- Stifel Nicolaus Initiates Coverage on Targa Resources Partners LP (NGLS) with a Hold
- Credit Suisse Restarts Coverage on MEMC Electronic Materials (WFR) with a Neutral
- Natixis Bleichroeder Initiates Coverage on AGA Medical (AGAM) with a Buy
- Leerink Swann Resumes Coverage on Medivation (MDVN) with an Outperform
- J.P. Morgan Initiates Coverage on Liberty Global (LBTYA) with a Neutral
Rodman & Renshaw initiates coverage of Enzo Biochem (NYSE: ENZ) with a Market Outperform / Speculative Risk rating and a 12-month target price of $14.
To see more analyst ratings on ENZ Click Here.
Enzo Biochem, Inc., a life sciences and biotechnology company, engages in research, development, manufacturing, and marketing of diagnostic and research products based on genetic engineering, biotechnology, and molecular biology.
Related Categories
New CoverageStocks Mentioned
+0.00Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
